Abilify (Schizophrenia) - Analysis and Forecasts to 2020

Abilify (Schizophrenia) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Abilify (Schizophrenia) - Analysis and Forecasts to 2020” provides Abilify sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Abilify including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Abilify including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Abilify in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Abilify – Analysis and Forecasts from 2002 to 2020 1
2 Table of Contents 2
2.1 List of Tables 3
2.2 List of Figures 3
3 Introduction 4
3.1 Schizophrenia 4
3.2 Symptoms 4
3.3 Schizophrenia Market 4
3.4 Epidemiology 4
3.5 Etiology 5
3.5.1 Genetic Factors 5
3.5.2 Environmental Factors 5
3.5.3 Abnormal Brain Structure 6
3.6 GlobalData Report Guidance 6
4 Schizophrenia: Market Characterization 7
4.1 Schizophrenia Market 7
4.2 Schizophrenia Market Forecasts and CAGR 7
4.3 Drivers of Schizophrenia Therapeutics Market 7
4.3.1 Patent Expiry of Leading Marketed Drugs 8
4.3.2 Increasing Patient Pool 8
4.3.3 High Prescription Rates 8
4.3.4 Low Patient Compliance Rate 8
4.3.5 High Unmet Need 8
5 Classification of Schizophrenia 9
5.1 Age of Onset of Schizophrenia 9
5.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
5.1.2 Adult Schizophrenia 10
5.2 Associated Symptoms 10
5.2.1 Paranoid Schizophrenia 10
5.2.2 Disorganized Schizophrenia 10
5.2.3 Catatonic Schizophrenia 10
5.2.4 Residual Schizophrenia 10
5.2.5 Undifferentiated Disorder 10
6 Treatment for Schizophrenia 11
6.1 Crisis Resolution Teams (CRT) 11
6.2 Voluntary and Compulsory Detention 11
6.3 Antipsychotics 11
6.3.1 Typical Antipsychotics 11
6.3.2 Atypical Antipsychotics 12
7 Abilify 13
7.1 Introduction 13
7.2 Agreement between Otsuka and BMS 13
7.3 Mechanism of Action 13
7.4 Clinical Studies 13
7.4.1 Adult Patients 13
7.4.2 Pediatric Patients 15
7.5 Approval History of Abilify 15
7.6 Factors Affecting Sales of Abilify 15
7.6.1 Better Efficacy 15
7.6.2 Continued Dominance by Newer Agents in Anti–Psychotic Market 16
7.6.3 Better Safety Profile 16
7.6.4 Agreement between Otsuka and BMS 16
7.6.5 Approval in Pediatric Patients 16
7.6.6 Patent Expiry of Abilify 16
7.7 Drug Evaluation 16
7.7.1 Drug Risk Benefit Score 16
7.7.2 Intensity of Competition 17
7.8 Sales Estimates 18
7.8.1 Target Patient Pool of Abilify 18
7.8.2 Dosing 18
7.8.3 Market Penetration 18
7.8.4 Annual Cost of Therapy 19
7.8.5 Sales Projections of Abilify 19
8 Schizophrenia Market: Appendix 29
8.1 Market Definitions 29
8.2 List of Abberiviations 29
8.3 Research Methodology 29
8.4 Contact Us 31
8.5 Disclaimer 32
8.6 Sources 32